Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic VTE compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic PE compared with placebo (low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic DVT compared with placebo (low certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
DOAC probably leads to lower any VTE compared with placebo (moderate certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC leads to lower symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review